Leveraging our high throughput technology 

First, Milagen generated antibody reagents and screened them against clinical samples (tissue, serum/plasma and urine) from cancer patients.

Second, we selected novel proteomic cancer biomarkers based on differential expression versus its control, and we utilized large sets of clinical samples from cancer patients to validate the biomarkers.

Based on our findings, we developed a portfolio of proprietary cancer biomarkers, with potential real-world clinical utility to monitor recurrence in cancer survivors.

© Milagen. All rights reserved.